Effect of Financial Incentives on Patient Use of Mailed Colorectal Cancer Screening Tests: A Randomized Clinical Trial.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
01 03 2019
Historique:
entrez: 23 3 2019
pubmed: 23 3 2019
medline: 26 11 2019
Statut: epublish

Résumé

Mailing fecal immunochemical test (FIT) kits to patients' homes has been shown to boost colorectal cancer screening rates, but response rates remain limited, and organized programs typically require repeated outreach attempts. Behavioral economics has shown that offering salient financial incentives to patients may increase participation in preventive health. To compare the impact of different financial incentives for mailed FIT outreach. This 4-parallel-arm randomized clinical trial included patients aged 50 to 75 years who had an established primary care clinician, at least 2 visits in the prior 2 years, and were eligible for colorectal cancer screening and not up-to-date. This study was conducted at urban primary care practices at an academic health system from December 2015 to February 2018. Data analysis was conducted from March 2018 to September 2018. Eligible patients received a letter from their primary care clinician that included a mailed FIT kit and instructions for use. They were randomized in a 1:1:1:1 ratio to receive (1) no financial incentive; (2) an unconditional $10 incentive included with the mailing; (3) a $10 incentive conditional on FIT completion; or (4) a conditional lottery with a 1-in-10 chance of winning $100 after FIT completion. Fecal immunochemical test completion within 2 and 6 months of initial outreach. A total of 897 participants were randomized, with a median age of 57 years (interquartile range, 52-62 years); 56% were women, and 69% were black. The overall completion rate across all arms was 23.5% at 2 months. The completion rate at 2 months was 26.0% (95% CI, 20.4%-32.3%) in the no incentive arm, 27.2% (95% CI, 21.5%-33.6%) in the unconditional incentive arm, 23.2% (95% CI, 17.9%-29.3%) in the conditional incentive arm, and 17.7% (95% CI, 13.0%-23.3%) in the lottery incentive arm. None of the arms with an incentive were statistically superior to the arm without incentive. The overall FIT completion rate across all arms was 28.9% at 6 months, and there was also no difference by arm. The completion rate at 6 months was 32.7% (95% CI, 26.6%-39.3%) in the no incentive arm, 31.7% (95% CI, 25.7%-38.2%) in the unconditional incentive arm, 26.8% (95% CI, 21.1%-33.1%) in the conditional incentive arm, and 24.3% (95% CI, 18.9%-30.5%) in the lottery incentive arm. Mailed FIT resulted in high colorectal cancer screening response rates in this population, but different forms of financial incentives of the same expected value ($10) did not incrementally increase FIT completion rates. The incentive value may have been too small or financial incentives may not be effective in this context. ClinicalTrials.gov Identifier: NCT02594150.

Identifiants

pubmed: 30901053
pii: 2728631
doi: 10.1001/jamanetworkopen.2019.1156
pmc: PMC6583304
doi:

Banques de données

ClinicalTrials.gov
['NCT02594150']

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e191156

Subventions

Organisme : NCI NIH HHS
ID : K08 CA234326
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA213645
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : ErratumIn

Références

JAMA Intern Med. 2018 Dec 1;178(12):1645-1658
pubmed: 30326005
Am J Prev Med. 2016 Oct;51(4):e107-15
pubmed: 27050413
Ann Intern Med. 2014 Nov 18;161(10 Suppl):S35-43
pubmed: 25402401
J Gen Intern Med. 2016 Nov;31(11):1323-1330
pubmed: 27412426
Gastroenterology. 2019 Jan;156(1):63-74.e6
pubmed: 30268788
N Engl J Med. 2012 Jun 21;366(25):2345-57
pubmed: 22612596
Cancer. 2004 Jan 15;100(2):418-24
pubmed: 14716780
J Gen Intern Med. 2014 May;29(5):770-7
pubmed: 24522623
Am J Gastroenterol. 2016 Nov;111(11):1630-1636
pubmed: 27481306
BMC Health Serv Res. 2013 Oct 29;13:449
pubmed: 24168208
Health Aff (Millwood). 2009 Jan-Feb;28(1):206-14
pubmed: 19124872
Cancer. 2011 Apr 15;117(8):1745-54
pubmed: 21472722
Science. 1981 Jan 30;211(4481):453-8
pubmed: 7455683
Epidemiol Rev. 2011;33:101-10
pubmed: 21709143
Gastroenterology. 2018 Nov;155(5):1383-1391.e5
pubmed: 30031768
Gastroenterology. 2017 Nov;153(5):1227-1229.e2
pubmed: 28734830
J Clin Epidemiol. 2015 Jun;68(6):693-7
pubmed: 25450450
Gut. 2018 Feb;67(2):291-298
pubmed: 27733426
Am J Health Promot. 2012 Jan-Feb;26(3):184-8
pubmed: 22208418
N Engl J Med. 2009 Feb 12;360(7):699-709
pubmed: 19213683
Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2170-5
pubmed: 19622721
Med Care. 1998 Jan;36(1):95-9
pubmed: 9431335
N Engl J Med. 2013 Sep 19;369(12):1095-105
pubmed: 24047059
Ann Fam Med. 2012 Sep-Oct;10(5):412-7
pubmed: 22966104
N Engl J Med. 1993 May 13;328(19):1365-71
pubmed: 8474513
JAMA. 2008 Dec 10;300(22):2631-7
pubmed: 19066383
J Med Screen. 2015 Sep;22(3):119-26
pubmed: 25967088
Am J Manag Care. 2015 Jul;21(7):511-7
pubmed: 26247741
Health Serv Res. 2011 Oct;46(5):1663-74
pubmed: 21492159
N Engl J Med. 2017 Oct 12;377(15):1412-1414
pubmed: 29020586
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Clin Gastroenterol Hepatol. 2014 May;12(5):711-4
pubmed: 24746170

Auteurs

Shivan J Mehta (SJ)

Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Penn Medicine Center for Health Care Innovation, University of Pennsylvania, Philadelphia.
Center for Health Incentives and Behavioral Economics, Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia.
Leonard and Madlyn Abramson Cancer Center, University of Pennsylvania, Philadelphia.

Rebecca S Pepe (RS)

Department of Family Medicine and Community Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

Nicole B Gabler (NB)

Department of Family Medicine and Community Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

Mounika Kanneganti (M)

Department of Family Medicine and Community Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

Catherine Reitz (C)

Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Department of Family Medicine and Community Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

Chelsea Saia (C)

Department of Family Medicine and Community Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

Joseph Teel (J)

Department of Family Medicine and Community Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

David A Asch (DA)

Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Penn Medicine Center for Health Care Innovation, University of Pennsylvania, Philadelphia.
Center for Health Incentives and Behavioral Economics, Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia.
Center for Health Equity Research and Promotion, Philadelphia VA Medical Center, Philadelphia, Pennsylvania.

Kevin G Volpp (KG)

Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Penn Medicine Center for Health Care Innovation, University of Pennsylvania, Philadelphia.
Center for Health Incentives and Behavioral Economics, Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia.
Center for Health Equity Research and Promotion, Philadelphia VA Medical Center, Philadelphia, Pennsylvania.

Chyke A Doubeni (CA)

Leonard and Madlyn Abramson Cancer Center, University of Pennsylvania, Philadelphia.
Department of Family Medicine and Community Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH